CALGARY, Alberta, Feb. 03, 2021 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of COVID-19 and other pathogens, today announced that it is actively working and achieving major milestones as the Company prepares its application for emergency use authorization (“EUA”) with the FDA.
Key activity includes:
- Clinical Trial Update: Advanced discussions are occurring daily with a notable, US-based healthcare system to begin significant clinical trials to determine the efficacy of the FluroTest Pandemic Defense System.
- Company Amalgamation: FluroTech and FluroTest joint efforts and expressed interest to amalgamate and consolidate have accelerated since entering into a Letter of Intent with a majority of the other FluroTest shareholders in a transaction that, when completed, will result in the Company acquiring up to 95% of FluroTest in Q1 2021.
- Coronavirus Variant Detection: Scientific team remains confident about the test detection capability for SARS-Cov-2 UK and South African variants.